National Association of Statutory Health Insurance Physicians

Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update

Retrieved on: 
Tuesday, May 2, 2023
LEPR, Polyphagia, Obesity, Food, International, Completeness, Body mass index, Bardet–Biedl syndrome, Food and Drug Administration, Clinical trial, Prescription, G&A, Advances in Therapy, Research, Ratio, POMC, BBS, CHI, Data analysis, Phase 3, Patient, Investment, Physician, PCSK1, National Association of Statutory Health Insurance Physicians, Webcast, MC4R, Ageing, R, BMI, FDA, Hunger, Acquisition, Human, Congenital hyperinsulinism, D, Pharmaceutical industry, Cryptocurrency, Rhythm, S

-- Management to host conference call today at 8:00 a.m. ET --

Key Points: 
  • ET --
    BOSTON, May 02, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today reported financial results and provided a business update for the first quarter ended March 31, 2023.
  • R&D Expenses: R&D expenses were $37.9 million in the first quarter of 2023, as compared to $32.5 million in the first quarter of 2022.
  • S,G&A Expenses: S,G&A expenses were $24.6 million for the first quarter of 2023, as compared to $21.4 million for the first quarter of 2022.
  • ET today to review its first quarter 2023 financial results and recent business activities.

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Retrieved on: 
Monday, April 24, 2023
Polyphagia, LEPR, Obesity, International, Prevalence, Life, Food and Drug Administration, Bardet–Biedl syndrome, Rhythm, Deficit spending, Polydactyly, Visual impairment, DSM-IV codes, POMC, BBS, Very early onset inflammatory bowel disease, Patient, PCSK1, National Association of Statutory Health Insurance Physicians, Medicine, European, Endocrinology, MC4R, FDA, EC, Hunger, Hypogonadism, Food, European Commission, Pharmaceutical industry, EU

The German Federal Joint Committee (G-BA) ruled that IMCIVREE is eligible for reimbursement by Statutory Health Insurances for BBS.

Key Points: 
  • The German Federal Joint Committee (G-BA) ruled that IMCIVREE is eligible for reimbursement by Statutory Health Insurances for BBS.
  • People living with BBS may experience insatiable hunger, also known as hyperphagia, and severe obesity beginning early in life.
  • In 2022, Rhythm was granted marketing authorization for IMCIVREE by the EC for BBS and early-access authorization for setmelanotide in France.
  • Rhythm expects to launch IMCIVREE for the treatment of patients with BBS in the Netherlands later this year and in Italy, Spain, and the UK in 2024.